MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
Moderna and Merck Announce mRNA-4157 (V940) in Combination with Keytruda ® (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 14, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda ® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
RAHWAY, N.J.& CAMBRIDGE, Mass.--(BUSINESS WIRE)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Suvorexant in Breast Cancer Survivors
Conditions: Breast Cancer; Insomnia Interventions: Drug: Suvorexant Tablets; Other: Placebo Control Sponsors: Medical University of South Carolina; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE) December 7, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Conditions: Systemic Lupus Erythematosus Interventions: Biological: MK-6194; Biological: Placebo Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma Interventions: Drug: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Sponsors: National Cancer Centre, Singapore; Merck Sharp& Dohme LLC; National Medical Research Council (NMRC), Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Solid Cancer Interventions: Drug: R-DXd; Drug: Gemcitabine; Drug: Paclitaxel; Drug: Topotecan; Drug: PLD Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Conditions: Glioblastoma Multiforme; Astrocytoma, Grade IV Interventions: Biological: Allogeneic cytomegalovirus-specific T cells; Drug: Pembrolizumab Sponsors: Queensland Institute of Medical Research; CUREator; Merck Sharp& Dohme LLC; The Newro Foundation; Royal Brisbane and Women ' s Hospital; Princess Alexandra Hospital, Brisbane, Australia; Austin Hospital, Melbourne Australia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials
Merck ’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021
Results from Phase 3 trial, STRIDE-3, to be presented at World... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer; Stage II Lung Cancer; Stage III Lung Cancer Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Etoposide; Biological: Pembrolizumab; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Radiation: Radiation Therapy Sponsors: Vanderbilt-Ingram Cancer Center; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2023 Category: Research Source Type: clinical trials
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Interventions: Drug: Nemtabrutinib; Drug: Ibrutinib; Drug: Acalabrutinib Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms Interventions: Drug: MK-5684; Drug: Dexamethasone; Drug: Fludrocortisone acetate; Drug: Hydrocortisone; Drug: Abiraterone acetate; Drug: Prednisone acetate; Drug: Enzalutamide Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Conditions: Neuromuscular Blocks Interventions: Drug: 2 mg/kg sugammadex; Drug: 0.07 mg/kg neostigmine Sponsors: The Cleveland Clinic; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)
Conditions: Prostate Cancer Metastatic Interventions: Drug: MK-5684; Drug: Abiraterone acetate; Drug: Enzalutamide; Drug: Hydrocortisone; Drug: Fludrocortisone acetate; Drug: Prednisone; Drug: Dexamethasone Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
